Caribou Biosciences (CRBU) Net Cash Flow (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Net Cash Flow data on file, last reported at -$303000.0 in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 102.31% year-over-year to -$303000.0 in Q1 2026; TTM through Mar 2026 was -$17.4 million, a 13.13% increase from a year earlier, with the FY2025 full-year figure at -$3.9 million, up 88.72% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$303000.0, down from $1.2 million in the prior quarter.
• Over the last five years, Net Cash Flow for CRBU reached as high as $37.9 million in Q3 2023 and fell as low as -$92.8 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$13.4 million across 5 years, with a median of -$5.9 million in 2024.
• Across the five-year window, Net Cash Flow sank 185.75% in 2024 and soared 844.84% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$23.7 million in 2022, then plunged by 122.75% to -$52.9 million in 2023, then jumped by 70.36% to -$15.7 million in 2024, then jumped by 107.96% to $1.2 million in 2025, then slumped by 124.28% to -$303000.0 in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$303000.0 in Q1 2026, $1.2 million in Q4 2025, and -$14.1 million in Q3 2025.